Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Angela Fernandez de Lascoiti"'
2
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Autor: Ruth Vera, Miren Zuazo, Idoia Morilla, Berta Hernandez, Hugo Arasanz, Maria Jose Lecumberri, Grazyna Kochan, Gonzalo Fernandez-Hinojal, David Escors, Ana Bocanegra, Maite Martínez, Maria Jesus Garcia-Granda, Lucia Teijeira, Maria Gato, Angela Fernandez de Lascoiti
Publikováno v: EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 11, Iss 7, Pp n/a-n/a (2019)
The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with funct
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e018261645b0fe085cb0595c726a1f
https://pubmed.ncbi.nlm.nih.gov/31273938
Zobrazit plný text záznamu
3
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
Autor: Angela Fernandez de Lascoiti, Maria Jose Lecumberri, Ruth Vera, Lucia Teijeira, Hugo Arasanz, Maria Jesus Garcia-Granda, David Escors, Gonzalo Fernandez-Hinojal, Idoia Morilla, M. Martínez-Aguillo, Miren Zuazo-Ibarra, Carlos Hernandez, Grazyna Kochan, Berta Hernandez-Marin, María Isabel Ibáñez, Ana Bocanegra
Publikováno v: Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname
International Journal of Molecular Sciences, Vol 20, Iss 7, p 1631 (2019)
International Journal of Molecular Sciences
Volume 20
Issue 7
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, PD-L1 is widely expressed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::923287e1be9e841b46c1375b9aab9713
https://hdl.handle.net/2454/43707
Zobrazit plný text záznamu
4
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Autor: Salvatore Grisanti, Tanja Fehm, Daniele Generali, Jean-Yves Pierga, Dimitrios Mavroudis, Mario Giuliano, Leticia De Mattos-Arruda, Steven Van Laere, Lorenzo Gerratana, Francesca Consoli, Wolfgang Janni, Klaus Pantel, Luc Dirix, Stefan Michiels, Carlos Caldas, Annemie Rutten, Jorge S. Reis-Filho, Michail Ignatiadis, Dieter Peeters, Andrew M. Davis, Sarah-Jane Dawson, Jose Vidal-Martinez, Cristina Raimondi, Massimo Cristofanilli, Alfred Rademaker, Maria Teresa Sandri, Justin Stebbing, Rita Zamarchi, Franziska Meier-Stiegen, Elisabetta Munzone, Jonathan Krell, Vicente Carañana, Erich-Franz Solomayer, Laura Zorzino, Franco Nolè, Paola Gazzaniga, Eduardo Díaz-Rubio, Lauren Darrigues, Luc Cabel, Rafael Gisbert-Criado, Eleni Politaki, Sofia Agelaki, José A. García-Sáenz, Angela Fernandez de Lascoiti, Maria Rosa Cappelletti, Camillo Almici, Luis Manso, François-Clément Bidard, James M. Reuben
Publikováno v: Critical reviews in oncology, hematology
Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ef4c527220afcd22fd71cd8f94b62a
https://hdl.handle.net/11368/2935442
Zobrazit plný text záznamu
6
Immunotherapy in malignant melanoma: recent approaches and new perspectives
Autor: Grazyna Kochan, David Escors, Miren Zuazo, Angela Fernandez de Lascoiti, Maria Gato-Cañas, Hugo Arasanz, Maria José Lecumberri, Idoia Blanco-Luquin, Alejandra Lacalle, Leyre Pérez-Ricarte
Publikováno v: Melanoma management. 4(1)
Immunotherapy has radically transformed the management of metastatic malignant melanoma. Ipilimumab, a CTLA-4-targeted monoclonal antibody, was the first immunotherapeutic drug to reach a survival benefit compared with traditional chemotherapy. PD-1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71ac5ef26c055e97f790ac6e7ad5e2ad
https://pubmed.ncbi.nlm.nih.gov/30190903
Zobrazit plný text záznamu
8
Is There Any Difference in Overall Response Rate According to Kras Mutation in Advanced Colorectal Cancer (Acrc)?
Autor: Javier Suárez, Ruth Vera, Marta Montes, D. Guerrero, Angela Fernandez de Lascoiti, José Antonio Rivadeneira Cabana, Maria Luisa Gomez Dorronsoro, Miguel Angel Ciga Lozano, Irene Hernandez, Antonio Tarifa, Antonio Viudez, Juan Verdun
Publikováno v: Annals of Oncology. 24:iv117
e14589 Background: Tejpar et al (JCO2012; 30(29):3570-7) showed that patients with aCRC and Gly13D kras mutation experienced worse response rate with chemotherapy alone compared to those with other kras mutations. This retrospective study analyzes di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35e97c2d0d28c3ac2ad940b4cd5943d
https://doi.org/10.1093/annonc/mdt203.288
Zobrazit plný text záznamu
9
Akademický článek
Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
Autor: Miren Zuazo, Hugo Arasanz, Gonzalo Fernández‐Hinojal, Maria Jesus García‐Granda, María Gato, Ana Bocanegra, Maite Martínez, Berta Hernández, Lucía Teijeira, Idoia Morilla, Maria Jose Lecumberri, Angela Fernández de Lascoiti, Ruth Vera, Grazyna Kochan, David Escors
Publikováno v: EMBO Molecular Medicine, Vol 11, Iss 7, Pp 1-14 (2019)
Abstract The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients w
Externí odkaz: https://doaj.org/article/3a88dbbc128d40bd80a8b975ab6348a4
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje